Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors
NCT02171663
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
BIBW 2992
Sponsor
Boehringer Ingelheim